Assuming the first $5m is added to revenue for the quarterly and hopefully included in cashflow. Then we will see some price action.
After years of burning money with little to show for it apart from a 2 year delayed FDA approval, you can understand why there is a little bitterness and disbelief that Lumos has finally turned around.
We are at the floor of that turnaround, and in time the wider market will see it as well.
Ann: Investor Briefing on new Hologic Agreements, page-96
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
